Iltefat Hamzavi, MD: The Role of JAK Inhibition in Treating Vitiligo

Iltefat Hamzavi, MD, discusses the evolving role of Janus kinase (JAK) inhibition in the treatment of vitiligo. He compares JAK inhibitors such as topical ruxolitinib cream to traditional treatment approaches while reviewing practical considerations for treatment selection and patient counseling. Dr. Hamzavi also explores treatment expectations across different body sites, the safety profile of topical JAK inhibition, and the role of combination approaches to optimize repigmentation outcomes for patients with vitiligo.